The Effect of Canakinumab on Clinical Outcomes in Patients With COVID-19: A Meta-Analysis

    March 2022 in “ Journal of Infection ”
    Guangyu Ao, Yushu Wang, Toni Li, Carolyn Tran, Qing Yang
    TLDR Canakinumab's effect on COVID-19 outcomes is unclear.
    The meta-analysis evaluated the effect of canakinumab, a biologic medication, on clinical outcomes in patients with COVID-19. Biologic medications, like canakinumab, were of interest due to their targeted action on immune system pathways. The study was conducted in the context of evolving SARS-CoV-2 variants, which had led to the rescinding of emergency use authorization for other treatments like bamlanivimab. The analysis aimed to assess the potential of canakinumab as a therapeutic option for COVID-19, although specific results and conclusions from the meta-analysis were not detailed in the provided text.
    Discuss this study in the Community →